The Current Ratio as of November 2024 (TTM) for Capricor Therapeutics, Inc. (CAPR) is 4.19

According to Capricor Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 4.19. This represents a change of 91.41% compared to the average of 2.19 of the last 4 quarters.

Capricor Therapeutics, Inc. (CAPR) Historical Current Ratio (quarterly & annually)

How has CAPR Current Ratio performed in the past?

The mean historical Current Ratio of Capricor Therapeutics, Inc. over the last ten years is 5.75. The current 4.19 Current Ratio has changed 7.19% with respect to the historical average. Over the past ten years (40 quarters), CAPR's Current Ratio was at its highest in in the June 2020 quarter at 18.91. The Current Ratio was at its lowest in in the June 2017 quarter at 0.82.

Capricor Therapeutics, Inc. (CAPR) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Capricor Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Capricor Therapeutics, Inc. (CAPR) Average Current Ratio

How has CAPR Current Ratio performed in the past?

The current Current Ratio of Capricor Therapeutics, Inc. (CAPR) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Capricor Therapeutics, Inc. (CAPR) Current Ratio vs. Peers

How is CAPR’s Current Ratio compared to its peers?

Capricor Therapeutics, Inc.’s Current Ratio is greater than Bio-Path Holdings, Inc. (0.86), greater than Catalyst Biosciences, Inc. (0), less than Diffusion Pharmaceuticals Inc. (10.96), less than NextCure, Inc. (9.07), less than Pulmatrix, Inc. (19.40), greater than Akari Therapeutics, Plc (0.29), less than Soleno Therapeutics, Inc. (17.26), greater than Unicycive Therapeutics, Inc. (3.61), greater than Cidara Therapeutics, Inc. (3.54), less than Phio Pharmaceuticals Corp. (6.38), greater than Onconova Therapeutics, Inc. (1.93), greater than Moleculin Biotech, Inc. (2.08), less than IDEAYA Biosciences, Inc. (22.93), less than AnaptysBio, Inc. (10.23), greater than MeiraGTx Holdings plc (2.34), less than Keros Therapeutics, Inc. (19.03), greater than Homology Medicines, Inc. (4.19),

Build a custom stock screener for Capricor Therapeutics, Inc. (CAPR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Capricor Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Capricor Therapeutics, Inc. (CAPR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Capricor Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.